SomnoMed Statistics
Total Valuation
SomnoMed has a market cap or net worth of 58.06 million. The enterprise value is 50.01 million.
| Market Cap | 58.06M |
| Enterprise Value | 50.01M |
Important Dates
The next estimated earnings date is Thursday, May 29, 2025.
| Earnings Date | May 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +108.63% |
| Shares Change (QoQ) | +42.66% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 103.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.94 |
| PB Ratio | 1.98 |
| P/TBV Ratio | 2.39 |
| P/FCF Ratio | 115.92 |
| P/OCF Ratio | 40.48 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.18, with an EV/FCF ratio of 99.85.
| EV / Earnings | -13.47 |
| EV / Sales | 0.78 |
| EV / EBITDA | 39.18 |
| EV / EBIT | n/a |
| EV / FCF | 99.85 |
Financial Position
The company has a current ratio of 1.81, with a Debt / Equity ratio of 0.12.
| Current Ratio | 1.81 |
| Quick Ratio | 1.52 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 2.96 |
| Debt / FCF | 7.30 |
| Interest Coverage | -3.09 |
Financial Efficiency
Return on equity (ROE) is -15.51% and return on invested capital (ROIC) is -2.92%.
| Return on Equity (ROE) | -15.51% |
| Return on Assets (ROA) | -2.14% |
| Return on Invested Capital (ROIC) | -2.92% |
| Return on Capital Employed (ROCE) | -4.58% |
| Revenue Per Employee | 206,790 |
| Profits Per Employee | -12,377 |
| Employee Count | 300 |
| Asset Turnover | 1.44 |
| Inventory Turnover | 6.94 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +37.57% in the last 52 weeks. The beta is 1.05, so SomnoMed's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +37.57% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 1.55 |
| Relative Strength Index (RSI) | 45.43 |
| Average Volume (20 Days) | 8,332 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SomnoMed had revenue of 62.04 million and -3.71 million in losses. Loss per share was -0.02.
| Revenue | 62.04M |
| Gross Profit | 37.23M |
| Operating Income | -1.47M |
| Pretax Income | -2.61M |
| Net Income | -3.71M |
| EBITDA | -337,262 |
| EBIT | -1.47M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 11.45 million in cash and 3.66 million in debt, giving a net cash position of 7.79 million.
| Cash & Cash Equivalents | 11.45M |
| Total Debt | 3.66M |
| Net Cash | 7.79M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 29.37M |
| Book Value Per Share | 0.14 |
| Working Capital | 11.54M |
Cash Flow
In the last 12 months, operating cash flow was 1.43 million and capital expenditures -933,560, giving a free cash flow of 500,850.
| Operating Cash Flow | 1.43M |
| Capital Expenditures | -933,560 |
| Free Cash Flow | 500,850 |
| FCF Per Share | n/a |
Margins
Gross margin is 60.01%, with operating and profit margins of -2.38% and -5.99%.
| Gross Margin | 60.01% |
| Operating Margin | -2.38% |
| Pretax Margin | -4.21% |
| Profit Margin | -5.99% |
| EBITDA Margin | -0.54% |
| EBIT Margin | -2.38% |
| FCF Margin | 0.81% |
Dividends & Yields
SomnoMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -108.63% |
| Shareholder Yield | -108.63% |
| Earnings Yield | -6.40% |
| FCF Yield | 0.86% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SomnoMed has an Altman Z-Score of 1.53. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.53 |
| Piotroski F-Score | n/a |